BSE filing, NSE: KESARENT. Summary written from the filing by ALFA Finder's alert engine.
Kesar Enterprises Ltd: key numbers
- Share price
- ₹9.26
- Market cap
- ₹93.34 Cr
- Revenue (annual)
- ₹304.5 Cr
- Net profit (annual)
- ₹-48.41 Cr
- P/E (TTM)
- -1.8×Sector 26.8×
- Promoter holding
- 70.53%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kesar Enterprises Ltd
All →Kesar Enterprises Merger & Restructuring Worth ₹431 Cr
Kesar Enterprises will sell its Sugar, Distillery, and Cogen divisions in a slump sale to Avadh Foods for Rs. 431 Crore.
- Value
- ₹431.0 Cr
- From
- Avadh Foods and Multi Warehouse Private Limited
Kesar Enterprises Debt & Borrowing
Kesar Enterprises accepted a One-Time Settlement sanctioned by the Sugar Development Fund via IFCI Limited. The settlement resolves outstanding dues under a Cogeneration Loan.
- Execution
- 6 months
Kesar Enterprises Results Update
Kesar Enterprises' Chairman's speech at the 91st AGM outlines FY 2025-26 performance. It reports revenue of ₹304.50 crore and a narrowed net loss of ₹48.41 crore.
Kesar Enterprises Annual General Meeting
Kesar Enterprises Limited held its 91st Annual General Meeting on August 20, 2026. Shareholders considered agenda items including financial statement adoption and related party transactions.
Kesar Enterprises Q1 FY27 Results: Net Loss of ₹18.5 Cr, Loss Widens
Kesar Enterprises Ltd reported a net loss of ₹18.5 Cr for Q1 FY27.
- Key figure
- Net loss ₹18.5 Cr
Kesar Enterprises Board Meeting Date
Kesar Enterprises Limited will convene a board meeting on August 13, 2026, to consider its unaudited financial results for the quarter ending June 30, 2026.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.